Clinical trials: Brest Cancer, open to volunteers
Breast Neoplasms Diagnosis, Brest Cancer
Wide-Angle Tomosynthesis and AI in Diagnostic Mammography
Breast cancer remains the most commonly diagnosed cancer and a leading cause of cancer-related mortality among women globally. Timely and accurate detection is crucial for improving prognosis and survival outcomes.
- Trial name
- NCT07491055
- Volunteers
- 1,400 people
- Sponsor
- Jean Seely
Brest Cancer ER+ and HER2 Negative
De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer
This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen…
- Trial name
- DELTA (NCT07866430)
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Montefiore Medical Center
Brest Cancer
Thyroid Dysfunction Induced by Radiotherapy Treatment in Patients with Breast Cancer
Breast cancer is the most common cancer and second most common cause of cancer death among US women,. External beam radiation therapy (RT) that involves the breast and regional lymph nodes, including axillary and supraclavicular…
- Trial name
- NCT06820554
- Volunteers
- 97 people
- Sponsor
- Assiut University
Head and Neck Tumor, Breast Cancer
Topical Diclofenac for Prevention of Radiation-induced Dermatitis
Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy.
- Trial name
- NCT06905561
- Testing
- Diclofenac Sodium Gel
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Brest Cancer
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
This study aims to explore the efficacy and safety of neratinib combined with fulvestrant and eribulin in the treatment of HR+/HER2+ advanced breast cancer after trastuzumab deruxtecan resistance.
- Trial name
- NETHER (NCT07333937)
- Testing
- Neratinib Combined with Fulvestrant and Eribulin
- Volunteers
- 35 people
- Sponsor
- Xijing Hospital
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo